Hester Biosciences has entered into a Business Transfer Agreement (BTA) with Innoves Animal Health, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy. Through the BTA, Hester has acquired the products, the brands and the marketing network of Innoves. All the employees of Innoves including the key management team have joined Hester. Innoves product brands - CURX, PROTIN-C, BETA4VET, HIFCR are well accepted in the dairy market.
This acquisition of the Innoves business is in line with Hester’s business plans to set up a Large Animal Health Division. Hester now has a ready platform to launch its Large Animal Health business which will not only market Innoves products, but also the Hester range of large animal products and large animal vaccines.
Hester would be launching its own large animal health product range through the newly acquired Innoves marketing infrastructure. The current distribution network and infrastructure of Hester would be utilized to distribute Innoves products, thereby sizably reducing distribution costs.
Hester has currently embarked on manufacturing PPR, Goat Pox, Brucella Abortus S-19 and Theileria - vaccines for large animals. PPR vaccine is part of the National Disease eradication program of the Government of India. The susceptible animal population for PPR is 212 million, making it a market for Rs. 800 million. Besides, there is a high demand of the vaccine in Asia and Southern Africa.
Hester will be the first company to commercially manufacture Goat Pox vaccine in India. The susceptible animal population for Goat Pox is 140 million, making it a market for Rs. 450 million. There is a good demand for this vaccine in Asia and Southern African countries.
The expected turnover from the Large Animal Health division of Hester, for the Indian market, in the first 12 months would be Rs. 100 million and is expected to grow at over 20% on a year to year basis.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1815.00 |
| Dr. Reddys Lab | 1351.50 |
| Cipla | 1476.15 |
| Lupin | 2172.00 |
| Zydus Lifesciences | 974.65 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
